4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺
| 中文名称 | 4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺 |
|---|---|
| 中文同义词 | 4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺;化合物JNJ-17203212;JNJ 17203212,TRPV1拮抗剂;化合物JNJ-17203212,10 MM DMSO 溶液;JNJ-17203212 (JNJ17203212;JNJ 17203212) |
| 英文名称 | 4-[3-(Trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide |
| 英文同义词 | 1-PiperazinecarboxaMide, 4-[3-(trifluoroMethyl)-2-pyridinyl]-N-[5-(trifluoroMethyl)-2-pyridinyl]-;N1-(3-Trifluoromethylpyrid-2-yl)-N4-(4-trifluoromethylpyrid-2-yl)carbamoylpiperazine;4-[3-(Trifluoromethyl)-2-pyridinyl]-N-[5-(trifluoromethyl)-2-pyridinyl]-1-piperazinecarboxamide;JNJ 17203212;JNJ-17203212 (JNJ17203212;management,inhibit,pain,migrainem,Transient receptor potential channels,TRP Channel,JNJ-17203212,JNJ17203212,Inhibitor,JNJ 17203212;4-(3-(Trifluoromethyl)pyridin-2-yl)-N-(5-(trifluoromethyl)pyridin-2-yl)piperazine-1-carboxamide;4-[3-(TRIFLUOROMETHYL)-PYRIDIN-2-YL]-N-[5-(TRIFLUOROMETH YL)-PYRIDIN-2-YL]-1-PIPERAZINECARBOXAMIDE |
| CAS号 | 821768-06-3 |
| 分子式 | C17H15F6N5O |
| 分子量 | 419.32 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 821768-06-3.mol |
| 结构式 |  |
4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺 性质
| 沸点 | 551.315±50.00 °C(Press: 760.00 Torr)(predicted) |
|---|---|
| 密度 | 1.472±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) |
| 储存条件 | Inert atmosphere,Room Temperature |
| 溶解度 | 二甲基亚砜：>20mg/mL |
| 酸度系数(pKa) | 9.323±0.46(predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至类白色 |
JNJ-17203212 是一种选择性、高效的，竞争性的 TRPV1 拮抗剂。JNJ-17203212 被开发用于疼痛处理的研究，如偏头痛。
|
TRPV1
|
JNJ-17203212 (0.5 μM) potently inhibits imperatorin-induced TRPV1 activation (Ca
2+
increases) in TRPV1-expressing HEK cells.
JNJ-17203212 (0.3 mg/kg ; i.v.) dose-dependently reduces inflammatory soup (IS)-induced the immediate early gene c-fos expression.
JNJ-17203212 completely blocks capsaicin-induced CGRP (the neurotransmitter calcitonin gene-related peptide) release in a dose-dependent manner.
| Animal Model: | Male Sprague-Dawley rats (260-300 g) |
| Dosage: | 0.3 mg/kg |
| Administration: | Intravenous injection |
| Result: | Had a dose-dependent effect on the elevated c-fos expression that occurred after intracisternal injection of IS. |
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-100129 | 4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺 JNJ-17203212 | 821768-06-3 | 5mg | 800元 |
| 2026/06/05 | HY-100129 | 4-(3-(三氟甲基)吡啶-2-基)-N-(5-三氟甲基)吡啶-2-基)哌嗪-1-甲酰胺 JNJ-17203212 | 821768-06-3 | 10mM * 1mLin DMSO | 880元 |